ArticleCNS neuroscience & therapeutics2026
Forsythoside A Alleviates Neuroinflammatory Damage via Inhibiting TLR4/NF-κB/NLRP3 Activation-Induced Astrocyte Pyroptosis in Cerebral Ischemia-Reperfusion.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neuroinflammatory cascade triggered by cerebral ischemia-reperfusion injury (CIRI) represents a pivotal pathological mechanism driving neuronal death and dysfunction. Forsythoside A (FA) exhibits anti-inflammatory properties, but its effects on CIRI and potential mechanisms remain unclear.
aimsTo investigate whether FA improves astrocyte pyroptosis and alleviates neuroinflammatory damage in CIRI via modulating the Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB)/NLRP3 pathway.
methodsThe middle cerebral artery occlusion reperfusion (MCAO/R) mouse model was established, with cerebral infarction volume observed through TTC staining, and neurological scores assessed. The effects of FA on cerebral cortical damage, neuroinflammation, apoptosis, and pyroptosis were observed by pathological staining. An oxygen-glucose deprivation/reoxygenation (OGD/R) U251 human astroglioma cell model was established, and the protective impact of FA on cell viability was detected through the cell counting kit-8 assay. The release of lactate dehydrogenase (LDH) was measured by the LDH assay Kit, and cell pyroptosis was evaluated through Hoechst 33,342/PI staining. Inflammatory factor levels were detected by ELISA kits, with pyroptosis-related and TLR4/NF-κB/NLRP3 pathway-related protein levels evaluated through Western blot.
resultsFA reduced the infarct volume, ameliorated brain tissue pathological damage, reduced activated astrocytes, and inhibited neuronal apoptosis in MCAO/R mice. FA also alleviated inflammatory cell infiltration in brain tissue and declined pro-inflammatory factor levels in serum. In addition, FA suppressed TLR4 and p-NF-κB p65 expression and NLRP3 inflammasome activation in astrocytes. OGD/R caused decreased U251 cell viability, increased LDH release, and pyroptosis rate, while FA treatment could reverse the above effects. Mechanistically, FA hindered the TLR4/NF-κB pathway, down-regulated NLRP3 and pyroptosis-related proteins. The TLR4 agonist LPS weakened the protective impact of FA on MCAO/R mice and OGD/R cell models.
conclusionFA alleviates neuroinflammatory damage through inhibiting the TLR4/NF-κB axis and blocking NLRP3 inflammasome-induced astrocyte pyroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.